Skip to main
  1. Stocks
  2. AtriCure
  3. Forecast
ATRC

AtriCure (ATRC) Stock Forecast & Price Target

AtriCure (ATRC) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

AtriCure is supported by broad-based U.S. strength, with Q3 revenue of $154.5M up 15.1% constant currency, led by Open Ablation and Pain Management growth of 17% and nearly 35%, while gross margin expanded to 77.3% and adjusted EBITDA nearly reached $27M. The company also raised 2026 guidance to $606M-$610M of sales and $91M-$94M of EBITDA, reflecting durable demand across its core franchises and improving operating leverage as clinicians adopt its therapies. Beyond the current quarter, the BoxX-NoAF trial is approaching full enrollment with a Spring ’27 readout expected, and management’s view that adjusted EBITDA could triple over three years underscores a compelling long-term fundamental backdrop.

Bears say

AtriCure is exposed to several concentrated execution risks, as disappointing sales from EPi-Sense/Convergent, softer-than-expected Open Ablation and AtriClip demand, and margin pressure could all undermine growth and profitability. Its outlook is further challenged by competitive threats, particularly potential market share loss to Medtronic’s Penditure surgical LAA closure device, which could weaken its position in a core cardiac surgery category. Given that the company relies on a direct sales force and distributors and generates a majority of revenue in the United States, any product shortfall or pricing pressure in its key end markets could quickly filter through to financial performance.

AtriCure (ATRC) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AtriCure and is not a guaranteed prediction by Public.com or investment advice.

AtriCure (ATRC) Analyst Forecast & Price Prediction

Get the latest AtriCure (ATRC) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in AtriCure (ATRC)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AtriCure (ATRC) Forecast

Analysts have given AtriCure (ATRC) a Buy based on their latest research and market trends.

According to 8 analysts, AtriCure (ATRC) has a Buy consensus rating as of Nov 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $64.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $64.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AtriCure (ATRC)


AtriCure (ATRC) Analyst Forecast & Price Prediction

Get the latest AtriCure (ATRC) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in AtriCure (ATRC)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ATRC stock data and trends